Research and Markets (http://www.researchandmarkets.com/research/f7e7a7/epigenetics_therap)
has announced the addition of the Epigenetics
Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in
Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
report to their offering.
“Epigenetics
Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in
Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma”
Epigenetics
Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in
Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma.
The report provides insights on segments where epigenetic therapies may
prove to be useful. The report also details the market potential for the
epigenetic therapies, Furthermore, it provides insights into the
epigenetic therapeutics R&D pipeline. The report also contains
comprehensive profiles of the epigenetic therapies in late-stage
clinical development. The report offers insights into the US, the top
five markets in Europe and Japan. The report also elucidates the current
competitive landscape of the epigenetic therapeutics market.
The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by a
team of industry experts.
Epigenetic drugs are the chemical compounds or biologics that cause
epigenetic changes resulting in modified molecular protein expressions.
These drugs have the potential to trigger or suppress a protein
expression process.
Currently, there are four epigenetic drugs in the market, namely Vidaza,
Zolinza, Dacogen and Istodax. The sales of these drugs will account for
all of the revenues of the epigenetic therapeutics market. The global
epigenetic therapeutics market measured in this report comprises the
sales of VIdaza, Zolinza, and Dacogen in the top seven markets of the
world.
Four Epigenetics Drugs Generated Revenues of $517m in 2009
Vidaza, Dacogen, Zolinza and Istodax are the four currently approved
epigenetic drugs in the market. The sales of these drugs amounted to
$517m in 2009. Vidaza and Dacogen are approved for the indication
Myelodysplastic Syndrome (MDS) and Zolinza and Istodax are approved for
the indication Cutaneous T-cell lymphoma (CTCL). Of all the drugs,
Vidaza had the largest market share in 2009, followed by Dacogen.
Vidaza and Dacogen Belong to a Class of Drugs called DNA
Methyltransferase Inhibitors that Dominate the Epigenetics Market
Vidaza and Dacogen belong to a new class of drugs called DNA
Methyltransferase inhibitors. These drugs cause the removal of the
methyl group from the cytosine residue in the DNA and cause the
repression of tumor genes. Of all the drugs, Vidaza and Dacogen are the
most commonly used drugs for the treatment of MDS. They are currently
employed by physicians as a second or third line of therapy.
The Epigenetic Therapies are Currently Only Approved for Blood Cancer
Epigenetic drugs are currently approved to treat MDS and CTCL, which are
cancers of the blood cells. MDS is a type of blood cancer that affects
the stem cells secreted in the bone marrow. CTCL affects the lymphocytes
that secrete T-cells. The accumulation of the proliferated T-lymphocytes
in the subcutaneous regions causes a rash-like appearance and progresses
to become metastasis.
Scope
Annualized market data from 2001 to 2009, forecast forward to 2016.
Analysis of the leading technology in this space
Market characterization
Key drivers and barriers that have a significant impact on the market.
Competitive benchmarking of leading companies.
Reasons to buy
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying
the leading therapeutic segments and geographic markets poised for
strong growth.
Reinforce R&D pipelines
Develop key strategic initiatives by understanding the key focus areas
of leading companies.
Exploit in-licensing and out-licensing opportunities by identifying
products that could fill portfolio gaps.
Key Topics Covered:
Introduction
Market Characterization: Global Epigenetics Market
In-Depth Analysis
Competitive Landscape
Epigenetic Therapeutics: Appendix
Companies Mentioned:
Merck & Co
Celgene Corporation
EISAI
For more information visit http://www.researchandmarkets.com/research/f7e7a7/epigenetics_therap
Source: Business Wire